GR2001

BIOLOGICAL2 trials

Sponsors

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Conditions

Tetanus

Phase 1

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

CompletedNCT06302374

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Tetanus

Start: 2023-03-04End: 2024-02-19Updated: 2024-03-08

Phase 3

A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

RecruitingNCT06635798

Genrix (Shanghai) Biopharmaceutical Co., Ltd.Tetanus

Start: 2024-09-03End: 2025-03-04Target: 582Updated: 2024-10-10